MedPal AI PLCLSE: MPAL

MedPal AI: Result of General Meeting

· Issued by MedPal AI PLC via RNS

Summary by 6ix AI

At its General Meeting held on October 29, 2026, MedPal AI plc, an AI-native digital health and pharmacy group, had all resolutions passed. As a result, it issued a total of 14,050,242 warrants (rights to buy shares at a set price) to Clear Capital in relation to historical fundraises.

Key details

  • 5,000,000 warrants have an exercise price of 8p and an exercise period ending on October 8, 2030.
  • 7,480,242 warrants have an exercise price of 5.01p and an exercise period ending on March 3, 2029.
  • 1,570,000 warrants have an exercise price of 2.5p and an exercise period ending on March 26, 2031.
  • The meeting follows MedPal's announcement of October 6, 2026. MedPal's shares trade on AIM, the London Stock Exchange's market for smaller companies, and in Frankfurt.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/result-of-general-meeting-538

29 October 2026

MedPal AI plc

("MedPal", the "Company" or the "Group")

Result of General Meeting

Issue of Warrants

Further to its announcement of 6 October 2026, MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy group, announces that announces that at the General Meeting of the Company held earlier today, all resolutions were duly passed. Accordingly, the Company has issued warrants to Clear Capital in relation to historical fundraises as shown below:

Number of Warrants

Exercise Price

Exercise Period

5,000,000

8p

the period ending on 8 October 2030

7,480,242

5.01p

the period ending on 3 March 2029

1,570,000

2.5p

the period ending on 26 March 2031

14,050,242

-

For further information please contact:

Enquiries:

MedPal AI plc

Jason Drummond, Chief Executive Officer

Via Square1 Consulting

Cairn Financial Advisers LLP (Nomad)

Louise O'Driscoll / Jo Turner

+44 (0) 20 7213 0880

Merlin Partners LLP (Broker)

+44 (0) 20 7839 3500

Clear Capital Markets Limited (Broker)

Bob Roberts

+44 (0) 20 3869 6080

Square1 Consulting - (Financial PR)

David Bick

+44 (0) 20 7929 5599 / +44 (0) 7831 381201

About MedPal AI plc

MedPal AI plc (AIM: MPAL; FRA: Z1N) is a vertically integrated, AI-native digital health and pharmacy group. The Group operates NHS Distance Selling Pharmacy hubs at Sarus Court, Runcorn and Swaffham, New Health (new.co.uk), a dedicated GLP-1 weight management clinic, a B2B care home pharmacy supply business, eMARx, the Group's electronic medication administration record software for care homes, and Juno, an agentic AI health companion built on Anthropic's Claude. MedPal's ambition is to build the UK's leading Health OS: a single platform connecting prescribing, dispensing, delivery, administration and AI-driven patient support. The Company's LEI is 984500EDP8B0A14CBA61.

END

MedPal AI PLC on 6ix

Earlier from MedPal AI

Later from MedPal AI

All MedPal AI news releases